SUPPLEMENTARY INFORMATION CHAPTER 6



Supplementary Figure 1. Generation of independent Ba/F3 cell lines overexpressing *SLC34A2-ROS1* with on-target mutations.



Supplementary Figure 2. (A) Patients with *CD74-ROS1* positive fusions versus non-*CD74-ROS1* fusions did not show a significant difference in progression-free survival (log-rank, p=0.257). (B) Similarly, there was no significant survival difference in progression-free survival between breakpoint exon 32 (long) vs. breakpoint exon 34 (short) groups (log-rank, p=0.231).

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming eml4-alk fusion gene in non-small-cell lung cancer. Nature 2007;448:7153:561-6 doi: 10.1038/nature05945.

2. Allouche M. Alk is a novel dependence receptor: Potential implications in development and cancer. Cell Cycle 2007;6:13:1533-8 doi: 10.4161/cc.6.13.4433.

3. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:9:3389-95 doi: 10.1158/0008-5472.CAN-07-6186.

4. Kelleher FC, McDermott R. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer 2010;46:13:2357-68 doi: 10.1016/j.ejca.2010.04.006.

5. Jefferson E. Fda approves xalkori with companion diagnostic for a type of late-stage lung cancer. https://wayback.archive-it.org/7993/20170112024013/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm.

6. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:18:1693-703 doi: 10.1056/NEJMoa1006448.

7. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in alk-positive lung cancer. N Engl J Med 2014;371:23:2167-77 doi: 10.1056/NEJMoa1408440.

8. Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in egfr-driven or alk-driven nsclc: First-generation or next-generation tki? Nat Rev Clin Oncol 2018;15:11:694-708 doi: 10.1038/s41571-018-0081-4.

9. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced alk-positive lung cancer. N Engl J Med 2013;368:25:2385-94 doi: 10.1056/NEJMoa1214886.

10. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular mechanisms of resistance to first- and second-generation alk inhibitors in alk-rearranged lung cancer. Cancer Discov 2016;6:10:1118-33 doi: 10.1158/2159-8290.CD-16-0596.

11. Lin JJ, Riely GJ, Shaw AT. Targeting alk: Precision medicine takes on drug resistance. Cancer Discov 2017;7:2:137-55 doi: 10.1158/2159-8290.CD-16-1123.

12. Dhillon S, Clark M. Ceritinib: First global approval. Drugs 2014;74:11:1285-91 doi: 10.1007/s40265-014-0251-3.

13. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, et al. Activity and safety of brigatinib in alk-rearranged non-small-cell lung cancer and other malignancies: A single-arm, open-label, phase 1/2 trial. Lancet Oncol 2016;17:12:1683-96 doi: 10.1016/S1470-2045(16)30392-8.

14. Syed YY. Lorlatinib: First global approval. Drugs 2019;79:1:93-8 doi: 10.1007/s40265-018-1041-0.

15. Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, et al. Lorlatinib versus crizotinib in patients with advanced alk-positive non-small cell lung cancer: 5-year outcomes from the phase iii crown study. J Clin Oncol 2024:JCO2400581 doi: 10.1200/JCO.24.00581.

16. Tabbo F, Reale ML, Bironzo P, Scagliotti GV. Resistance to anaplastic lymphoma kinase inhibitors: Knowing the enemy is half the battle won. Transl Lung Cancer Res 2020;9:6:2545-56 doi: 10.21037/tlcr-20-372.

17. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in alk-rearranged lung cancers. Sci Transl Med 2012;4:120:120ra17 doi: 10.1126/scitranslmed.3003316.

18. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with alk gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:5:1472-82 doi: 10.1158/1078-0432.CCR-11-2906.

19. Li W, Kok K, Tan GW, Meng P, Mastik M, Rifaela N, et al. The presence of egfr t790m in tki-naive lung cancer samples of patients who developed a t790m-positive relapse on first or second generation tki is rare. Cancers (Basel) 2022;14:14 doi: 10.3390/cancers14143511.

20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1). Eur J Cancer 2009;45:2:228-47 doi: 10.1016/j.ejca.2008.10.026.

21. Sidorenkov G, Nagel J, Meijer C, Duker JJ, Groen HJM, Halmos GB, et al. The oncolifes data-biobank for oncology: A comprehensive repository of clinical data, biological samples, and the patient's perspective. J Transl Med 2019;17:1:374 doi: 10.1186/s12967-019-2122-x.

22. Koopman B, Groen HJM, Schuuring E, Hiltermann TJN, Timens W, den Dunnen WFA, et al. Actionability of on-target alk resistance mutations in patients with non-small cell lung cancer: Local experience and review of the literature. Clin Lung Cancer 2022;23:2:e104-e15 doi: 10.1016/j.cllc.2021.06.011.

23. O'Leary B, Hrebien S, Beaney M, Fribbens C, Garcia-Murillas I, Jiang J, et al. Comparison of beaming and droplet digital pcr for circulating tumor DNA analysis. Clin Chem 2019;65:11:1405-13 doi: 10.1373/clinchem.2019.305805.

24. Milosevic D, Mills JR, Campion MB, Vidal-Folch N, Voss JS, Halling KC, et al. Applying standard clinical chemistry assay validation to droplet digital pcr quantitative liquid biopsy testing. Clin Chem 2018;64:12:1732-42 doi: 10.1373/clinchem.2018.291278.

25. Arnolda R, Howlett K, Chan T, Raleigh J, Hatzimihalis A, Bell A, et al. Clinical validation and implementation of droplet digital pcr for the detection of braf mutations from cell-free DNA. Pathology 2022;54:6:772-8 doi: 10.1016/j.pathol.2022.02.010.

26. Lettig L, Sahnane N, Pepe F, Cerutti R, Albeni C, Franzi F, et al. Egfr t790m detection rate in lung adenocarcinomas at baseline using droplet digital pcr and validation by ultra-deep next generation sequencing. Transl Lung Cancer Res 2019;8:5:584-92 doi: 10.21037/tlcr.2019.09.18.

27. Pan Y, Deng C, Qiu Z, Cao C, Wu F. The resistance mechanisms and treatment strategies for alk-rearranged non-small cell lung cancer. Front Oncol 2021;11:713530 doi: 10.3389/fonc.2021.713530.

28. Dagogo-Jack I, Shaw AT. Crizotinib resistance: Implications for therapeutic strategies. Ann Oncol 2016;27 Suppl 3:Suppl 3:iii42-iii50 doi: 10.1093/annonc/mdw305.

29. Diaz-Cano SJ. Tumor heterogeneity: Mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci 2012;13:2:1951-2011 doi: 10.3390/ijms13021951.

30. Kahana-Edwin S, Cain LE, McCowage G, Darmanian A, Wright D, Mullins A, et al. Neuroblastoma molecular risk-stratification of DNA copy number and alk genotyping via cell-free circulating tumor DNA profiling. Cancers (Basel) 2021;13:13 doi: 10.3390/cancers13133365.

31. Lodrini M, Wunschel J, Thole-Kliesch TM, Grimaldi M, Sprussel A, Linke RB, et al. Circulating cell-free DNA assessment in biofluids from children with neuroblastoma demonstrates feasibility and potential for minimally invasive molecular diagnostics. Cancers (Basel) 2022;14:9 doi: 10.3390/cancers14092080.

32. Leest PV, Janning M, Rifaela N, Azpurua MLA, Kropidlowski J, Loges S, et al. Detection and monitoring of tumor-derived mutations in circulating tumor DNA using the ultraseek lung panel on the massarray system in metastatic non-small cell lung cancer patients. Int J Mol Sci 2023;24:17 doi: 10.3390/ijms241713390.